<DOC>
	<DOCNO>NCT01100151</DOCNO>
	<brief_summary>The purpose study assess safety tolerability RDC-1036 ( ALKS 37 ) adult opioid-induced constipation ( OIC ) follow repeat dose administration</brief_summary>
	<brief_title>ALK37-003 : A Study RDC-1036 ( ALKS 37 ) Adults With Opioid-induced Constipation ( OIC )</brief_title>
	<detailed_description>Approximately 60 subject enrol 1 2 cohort . Following review Cohort 1 safety tolerability data , subject enrol Cohort 2 , explore additional dos . Dose escalation occur cohort . There 18 visit 6-week period .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>18 70 year age Body mass index ( BMI ) 19 35 kg/m2 screen Receiving prescribe opioid medication management chronic , noncancer , pain Diagnosis opioidinduced constipation ( OIC ) Willingness stop laxative bowel regimen first study visit follow screen end study . The use constipation rescue medication allow study . Pregnancy and/or currently breastfeed Clinically significant medical condition illness ( condition pain medication prescribe ) Receiving treatment opioid therapy cancerrelated pain , abdominal pain , scleroderma , and/or management drug addiction Any gastrointestinal ( GI ) pelvic disorder know affect bowel transit , produce GI obstruction , contribute bowel dysfunction opioidinduced constipation ( eg , diverticulitis , intestinal stricture , bezoars ) Use medical device pacemaker , infusion pump , insulin pump Use naloxone , Subutex Suboxone , Revia , Relistor , Entereg start 15 day first study visit follow screen end study Participation clinical trial pharmacological agent within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Opioid-induced constipation</keyword>
	<keyword>RDC-1036</keyword>
	<keyword>ALKS 37</keyword>
</DOC>